A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Фаза 3 Завершено NCT05899816

Кратко

The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24

Percentage of Participants With a Positive Anti-tetanus Response at Week 24

Week 20 to Week 24 · percentage of participants

Percentage of Participants With a Positive Anti-meningococcal Response at Week 24

Week 20 to Week 24 · percentage of participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
• Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
• BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital

Все исследования